Deep Origin - About the company
Deep Origin is a series B company based in San Francisco (United States), founded in 2022 by Michael Antonov and Garegin Papoian. It operates as an AI-powered tools to accelerate drug discovery programs. Deep Origin has raised $25.5M in funding. The company has 148 active competitors, including 64 funded and 10 that have exited. Its top competitors include companies like Recursion Pharmaceuticals, XtalPi and Schrodinger.
Company Details
AI-powered tools to accelerate drug discovery programs. The company is focused on developing tools which include ComputeBench to assist scientists in solving diseases and extending healthspan through streamlined computational analysis and the simulation of biology.
- Website
- www.deeporigin.com/
- Social
- Email ID
- *****@deeporigin.com
- Registered Address
- 1000 WOODBURY RD STE 102,WOODBURY,NY,11797,0
Key Metrics
Founded Year
2022
Location
San Francisco, United States
Stage
Series B
Total Funding
$25.5M in 1 round
Latest Funding Round
Ranked
53rd among 148 active competitors
Employee Count
93 as on Jan 31, 2026
Similar Companies
Legal entities associated with Deep Origin
Deep Origin is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
DEEP ORIGIN INC CIN: 32089973682 , United States, Active | - | - | - |
Sign up to download Deep Origin's company profile
Deep Origin's funding and investors
Deep Origin has raised a total funding of $25.5M over 1 round.
Here is the list of recent funding rounds of Deep Origin:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 31, 2024 | 4978230 | Series B | 9345346 | 9421866 | 1487207 | 4184429 |
Access funding benchmarks and valuations. Sign up today!View details of Deep Origin's funding rounds and investors
Deep Origin's founders and board of directors
Founder? Claim ProfileThe founders of Deep Origin are Michael Antonov and Garegin Papoian. Michael Antonov is the CEO of Deep Origin.
Here are the details of Deep Origin's key team members:
- Michael Antonov: Co-Founder & CEO of Deep Origin.
- Garegin Papoian: Co-Founder of Deep Origin. Contact Info: 1 email address
View details of Deep Origin's Founder profiles and Board Members
Deep Origin's employee count trend
Deep Origin has 93 employees as of Jan 26. Here is Deep Origin's employee count trend over the years:
Uncover Deep Origin's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Deep Origin's Competitors and alternates
Top competitors of Deep Origin include Recursion Pharmaceuticals, XtalPi and Schrodinger. Here is the list of Top 10 competitors of Deep Origin, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Recursion Pharmaceuticals 2013, New York (United States), Public | AI-enabled drug discovery and development platform for novel therapeutics | $452M | 72/100 | |
2nd |  XtalPi 2014, Cambridge (United States), Public | AI-based drug research and development company | $785M | 67/100 | |
3rd |  Schrodinger 1990, New York City (United States), Acquired | Provider of a web-based simulation and modelling tool | $162M | 66/100 | |
4th |  Healx 2014, Cambridge (United Kingdom), Series C | AI-powered drug discovery platform to treat rare diseases | $115M | 64/100 | |
5th |  Xaira 2023, San Francisco (United States), Series D | AI-enabled platform for drug discovery and development | $1B | 63/100 | |
6th |  METiS Therapeutics 2017, Cambridge (United States), Series B | Provider of an AI-assisted platform for drug discovery and development | $252M | 63/100 | |
7th |  Valo Health 2019, Boston (United States), Series B | AI-powered platform for drug discovery and development | $450M | 62/100 | |
8th | Provider of an AI and quantum physics to discover therapeutic molecules | $103M | 62/100 | ||
9th |  In Silico 2014, Cambridge (United States), Public | AI-enabled bioinformatics platform for drug discovery and biomarker development | $510M | 62/100 | |
10th |  Isomorphic Labs 2021, London (United Kingdom), Series D | AI-driven platform to accelerate drug discovery process | $600M | 62/100 | |
53rd |  Deep Origin 2022, San Francisco (United States), Series B | AI-powered tools to accelerate drug discovery programs | $25.5M | - | 39/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Deep Origin's competitors? Click here to see the top ones
Deep Origin's Investments and acquisitions
Deep Origin has made no investments or acquisitions yet.
News related to Deep Origin
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Deep Origin
Explore our recently published companies
- Dancepoint - Unfunded company
- Farmairinc - 2017 founded, Unfunded company
- Beachfeet - 2003 founded, Unfunded company
- Tedsports - 2001 founded, Unfunded company
- Sensibleshoe - 2005 founded, Unfunded company
- Korkers - 1959 founded, Unfunded company
